Squamous Cell Carcinoma - Pipeline Review, H2 2014

Date: October 30, 2014
Pages: 145
Price:
US$ 2,000.00 US$ 1,500.00
Offer valid until December 31, 2016!
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: SFC2BE2F62DEN
Leaflet:

Download PDF Leaflet

Summary

Global Markets Direct’s, ‘Squamous Cell Carcinoma - Pipeline Review, H2 2014’, provides an overview of the Squamous Cell Carcinoma’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Squamous Cell Carcinoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Squamous Cell Carcinoma and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope
  • The report provides a snapshot of the global therapeutic landscape of Squamous Cell Carcinoma
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Squamous Cell Carcinoma and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Squamous Cell Carcinoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Squamous Cell Carcinoma pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
Reasons to buy
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Squamous Cell Carcinoma
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Squamous Cell Carcinoma pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Introduction
Global Markets Direct Report Coverage
Squamous Cell Carcinoma Overview
Therapeutics Development
Pipeline Products for Squamous Cell Carcinoma - Overview
Pipeline Products for Squamous Cell Carcinoma - Comparative Analysis
Squamous Cell Carcinoma - Therapeutics under Development by Companies
Squamous Cell Carcinoma - Therapeutics under Investigation by Universities/Institutes
Squamous Cell Carcinoma - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Squamous Cell Carcinoma - Products under Development by Companies
Squamous Cell Carcinoma - Products under Investigation by Universities/Institutes
Squamous Cell Carcinoma - Companies Involved in Therapeutics Development
AbbVie Inc.
Axelar AB
Bexion Pharmaceuticals, LLC.
Boehringer Ingelheim GmbH
Celgene Corporation
Clinuvel Pharmaceuticals Limited
Eli Lilly and Company
G&E Herbal Biotechnology Co., Ltd.
Genextra S.p.a.
Genmab A/S
Hutchison MediPharma Limited
InMed Pharmaceuticals Inc.
Karyopharm Therapeutics, Inc.
Neotropix, Inc.
Omeros Corporation
Oncolytics Biotech Inc.
Onconova Therapeutics, Inc.
Oncovir, Inc.
Otsuka Holdings Co., Ltd.
Pfizer Inc.
Sanofi
Squamous Cell Carcinoma - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
afamelanotide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
afatinib - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AMXT-1501 + eflornithine hydrochloride - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Antibody Drug Conjugate to Inhibit EFGR for Squamous Cell Tumor and Glioblastoma - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AXL-1717 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
boanmycin hydrochloride - Drug Profile
Product Description
Mechanism of Action
R&D Progress
BXQ-350 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CIGB-128 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CS-S/BCC-1 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CS-TATI-1 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CUV-9900 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
DAC-0060 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
dacomitinib - Drug Profile
Product Description
Mechanism of Action
R&D Progress
HMPL-453 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
LY-2606368 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NTX-500 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
OPB-111001 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
paclitaxel albumin bound - Drug Profile
Product Description
Mechanism of Action
R&D Progress
pelareorep - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Poly-ICLC - Drug Profile
Product Description
Mechanism of Action
R&D Progress
rigosertib sodium - Drug Profile
Product Description
Mechanism of Action
R&D Progress
SAR-408701 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
selinexor - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecule to Antagonize GPR39 for Esophageal Squamous Cell Carcinoma and Obesity-Related Type-2 Diabetes - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecule to Antagonize GPR87 for Cancer - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecules for Cancer - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecules to Inhibit PLK1 for Cutaneous Squamous Cell Carcinoma - Drug Profile
Product Description
Mechanism of Action
R&D Progress
SRT-100 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
TF-011 Monomethyl Auristatin E - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Squamous Cell Carcinoma - Recent Pipeline Updates
Squamous Cell Carcinoma - Dormant Projects
Squamous Cell Carcinoma - Discontinued Products
Squamous Cell Carcinoma - Product Development Milestones
Featured News & Press Releases
Sep 27, 2014: Head-to-head Phase III trial demonstrates superior progression-free survival for afatinib compared to erlotinib in patients with advanced squamous cell carcinoma of the lung
Mar 28, 2013: Oncolytics Biotech Meets Primary Overall Statistical Endpoint In US Phase II Study Of Reolysin In Squamous Cell Lung Cancer
Feb 08, 2013: Oncolytics Biotech Announces Additional Positive Reolysin Clinical Trial Data From Phase II Study In Squamous Cell Carcinoma Of Lung
Sep 24, 2012: Cannabis Science Initiates Preclinical Investigation Of CS-TATI-1 For European Studies For Squamous/Basal Cell Carcinomas And Kaposi’s Sarcoma
Mar 30, 2010: Oncolytics Announces Start Of Enrollment In US Phase II SCC Lung Cancer Trial
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products under Development for Squamous Cell Carcinoma, H2 2014
Number of Products under Development for Squamous Cell Carcinoma - Comparative Analysis, H2 2014
Number of Products under Development by Companies, H2 2014
Number of Products under Development by Companies, H2 2014 (Contd..1)
Number of Products under Investigation by Universities/Institutes, H2 2014
Comparative Analysis by Late Stage Development, H2 2014
Comparative Analysis by Clinical Stage Development, H2 2014
Comparative Analysis by Early Stage Development, H2 2014
Products under Development by Companies, H2 2014
Products under Development by Companies, H2 2014 (Contd..1)
Products under Investigation by Universities/Institutes, H2 2014
Squamous Cell Carcinoma - Pipeline by AbbVie Inc., H2 2014
Squamous Cell Carcinoma - Pipeline by Axelar AB, H2 2014
Squamous Cell Carcinoma - Pipeline by Bexion Pharmaceuticals, LLC., H2 2014
Squamous Cell Carcinoma - Pipeline by Boehringer Ingelheim GmbH, H2 2014
Squamous Cell Carcinoma - Pipeline by Celgene Corporation, H2 2014
Squamous Cell Carcinoma - Pipeline by Clinuvel Pharmaceuticals Limited, H2 2014
Squamous Cell Carcinoma - Pipeline by Eli Lilly and Company, H2 2014
Squamous Cell Carcinoma - Pipeline by G&E Herbal Biotechnology Co., Ltd., H2 2014
Squamous Cell Carcinoma - Pipeline by Genextra S.p.a., H2 2014
Squamous Cell Carcinoma - Pipeline by Genmab A/S, H2 2014
Squamous Cell Carcinoma - Pipeline by Hutchison MediPharma Limited, H2 2014
Squamous Cell Carcinoma - Pipeline by InMed Pharmaceuticals Inc., H2 2014
Squamous Cell Carcinoma - Pipeline by Karyopharm Therapeutics, Inc., H2 2014
Squamous Cell Carcinoma - Pipeline by Neotropix, Inc., H2 2014
Squamous Cell Carcinoma - Pipeline by Omeros Corporation, H2 2014
Squamous Cell Carcinoma - Pipeline by Oncolytics Biotech Inc., H2 2014
Squamous Cell Carcinoma - Pipeline by Onconova Therapeutics, Inc., H2 2014
Squamous Cell Carcinoma - Pipeline by Oncovir, Inc., H2 2014
Squamous Cell Carcinoma - Pipeline by Otsuka Holdings Co., Ltd., H2 2014
Squamous Cell Carcinoma - Pipeline by Pfizer Inc., H2 2014
Squamous Cell Carcinoma - Pipeline by Sanofi, H2 2014
Assessment by Monotherapy Products, H2 2014
Assessment by Combination Products, H2 2014
Number of Products by Stage and Target, H2 2014
Number of Products by Stage and Mechanism of Action, H2 2014
Number of Products by Stage and Route of Administration, H2 2014
Number of Products by Stage and Molecule Type, H2 2014
Squamous Cell Carcinoma Therapeutics - Recent Pipeline Updates, H2 2014
Squamous Cell Carcinoma - Dormant Projects, H2 2014
Squamous Cell Carcinoma - Discontinued Products, H2 2014

LIST OF FIGURES

Number of Products under Development for Squamous Cell Carcinoma, H2 2014
Number of Products under Development for Squamous Cell Carcinoma - Comparative Analysis, H2 2014
Number of Products under Development by Companies, H2 2014
Number of Products under Investigation by Universities/Institutes, H2 2014
Comparative Analysis by Late Stage Development, H2 2014
Comparative Analysis by Clinical Stage Development, H2 2014
Comparative Analysis by Early Stage Products, H2 2014
Assessment by Monotherapy Products, H2 2014
Number of Products by Top 10 Targets, H2 2014
Number of Products by Stage and Top 10 Targets, H2 2014
Number of Products by Top 10 Mechanism of Actions, H2 2014
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2014
Number of Products by Top 10 Routes of Administration, H2 2014
Number of Products by Stage and Top 10 Routes of Administration, H2 2014
Number of Products by Top 10 Molecule Types, H2 2014
Number of Products by Stage and Top 10 Molecule Types, H2 2014
Skip to top


Ask Your Question

Squamous Cell Carcinoma - Pipeline Review, H2 2014
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: